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Objectives: Clostridium difficile infection (CDI) costs the US health care system over 
$3 billion annually. Current guidelines recommend metronidazole as first-line ther-
apy in most instances of CDI. However, vancomycin is recommended for recurrent 
CDI (RCDI). A growing body of evidence supports the use of fecal microbiota trans-
plantation (FMT) as a therapeutic option for RCDI. This study explores cost-effec-
tiveness of FMT and vancomycin versus metronidazole for initial CDI. MethOds: 
We constructed a decision-analytic computer simulation using inputs from the pub-
lished literature to compare a 10-14-day course of oral metronidazole or vancomycin 
to FMT for initial CDI. Parameters included cure rates (range) for metronidazole [80% 
(65-85%)], vancomycin [90% (88-92%)] and FMT [91% (83-100%)]. The direct costs 
(range) of metronidazole, vancomycin and FMT, adjusted to 2011 dollars, were $57 
($43-72), $1347 ($1195-1499) and $1086 ($815-1358), respectively. Our effectiveness 
measure was quality-adjusted life years (QALYs). Analysis was performed from the 
3rd-party payer perspective and one-way and probabilistic sensitivity analyses were 
conducted. Results: Base case analysis showed that FMT ($1585, 0.242 QALYs) was 
more costly and more effective than metronidazole ($1167, 0.238 QALYs), yielding 
an ICER of $101,647/QALY. FMT was dominant (less expensive and more effective) 
compared to vancomycin ($1890, 0.241 QALYs). One-way sensitivity analyses showed 
that metronidazole dominated both competing strategies if its probability of cure 
was > 90%; FMT dominated if it cost < $667. In a probabilistic sensitivity analysis at 
a willingness-to-pay threshold of $100,000/QALY, metronidazole was favored in 50% 
of model iterations; FMT was favored in 45%. cOnclusiOns: Our results suggest 
that metronidazole, as the first-line treatment for CDIs, may be less costly, but that 
FMT and vancomycin are more effective. However, FMT is less likely to be economi-
cally favorable, and vancomycin is unlikely to be favorable as first line therapy when 
compared to FMT, due to higher cost and less effectiveness.
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Objectives: Based on a recent indirect treatment comparison, golimumab showed 
comparability in efficacy and safety to infliximab and superiority to adalimumab in 
efficacy in terms of sustaining clinical outcomes. For this reason, a cost-effectiveness 
(CE) analysis comparing the three anti-TNF-α agents was conducted. MethOds: 
A Markov model was created to simulate patients over 10 years. The first admin-
istered intervention was any of the three biologics. Health states included clinical 
remission, clinical response, and relapse. Upon relapsing with the administered 
biologic, patients were assumed to transition into ‘relapse management’. Patients 
would then undergo colectomy and enter ‘post-colectomy remission’. Utilities were 
assigned separately for states before and after colectomy. Canadian cost estimates 
were used. Uncertainty around transition probabilities and cost estimates were 
incorporated. Sensitivity analyses included a societal perspective, varying discount 
rates, and time horizons, and ‘real world’ transition probabilities. Measures included 
total cost and utility over 10 years, mean incremental cost and utility per year, 
incremental CE ratios (ICERs), CE acceptability curves (CEACs) for golimumab and 
the CE frontier for all biologics. Results: In all analyses, golimumab yielded the 
lowest ICER. In the base case analysis, golimumab, infliximab, and adalimumab 
were associated with ICERs of approximately $40,000/QALY, $80,000/QALY, and 
$100,000/QALY, respectively. The CEAC for golimumab showed that a willingness-
to-pay threshold (WTPs) of $100,000/QALY was associated with a ~90% probability 
of being cost-effective. The cost-effectiveness frontier demonstrated that WTP 
thresholds greater than $25,000 showed that golimumab had the greatest prob-
ability of being cost-effective. Golimumab and infliximab displayed extended domi-
nance compared to adalimumab. Sensitivity analysis taking a societal perspective 
or using ‘real world’ transition probabilities reduced the ICERs by 20-40% for all 
biologics. cOnclusiOns: Overall golimumab provides a cost-effective treatment 
option for patients who have had an inadequate response to conventional therapy 
for moderately to severely active ulcerative colitis.
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Objectives: To evaluate the long-term impact of linaclotide on work productivity 
and activity impairment in adults with irritable bowel syndrome with constipa-
tion (IBS-C). MethOds: In a 26-week phase 3 trial, 804 adults meeting modified 
Rome II criteria for IBS-C were randomized to oral once-daily 290-mcg linaclotide or 
placebo. The self-administered 6-item Work Productivity and Activity Impairment 
Questionnaire for IBS-C (WPAI:IBS-C) evaluated IBS-C-related absenteeism (work 
hours missed), presenteeism (lost productivity at work), overall work productiv-
ity loss (absenteeism + presenteeism), and daily activity impairment (housework, 
shopping, childcare, exercising, etc) over the previous week at baseline and weeks 
4, 8, 12, 16, 20, and 26 during the treatment period. Overall work productivity losses 
were converted into monetary values using the human capital method by multiply-
ing total hours lost by average hourly employment cost of a US employee ($31.16 
in September 2013). Results: Of 804 patients, 780 (97.0%) completed a baseline 
and ≥ 1 postbaseline WPAI:IBS-C assessment. Of these, 586 patients (75.1%) were 
currently employed. Linaclotide treatment was associated with statistically signifi-
cant reductions in presenteeism, overall work productivity loss, and daily activity 
conducted to identify economic evaluations of IBD therapy reporting incremental 
cost-effectiveness or cost-utility ratios (ICERs or ICURs). The literature search was 
performed using electronic databases. Searches were limited to full economic evalu-
ations published in English or French between 2003 and 2013. Cross-reference of 
retrieved articles was also performed to identify additional publications. Results: 
A total of 15,242 potentially relevant studies were identified. After screening titles 
and abstracts, 43 full-text articles were assessed according to the eligibility criteria 
and 35 studies were included. Among those, 3 studies assessed the economic impact 
of IBD treatments with a companion diagnostic test. A high proportion of economic 
evaluations was performed from a third party payer perspective (91%) and had time 
horizons of 1 year or less (46%). European, American and Canadian economic evalua-
tions accounted for 66%, 17% and 11% of the studies respectively. Treatment options 
under evaluation included azathioprine, infliximab, adalimumab, immunosuppres-
sant and mesalamine. Most included studies were cost-utility analyses (94%), with 
ICURs ranging from dominant to CAD$11,934,934/QALY. More specifically, treatment 
under investigation was dominant in 26% of the analyses and was cost-effective 
according to a CAD$50,000/QALY and a CAD$100,000/QALY threshold in 31% and 
65% of the analyses respectively. cOnclusiOns: Several economic evaluations 
were conducted in the past years, with different parameters and results. As more 
treatment options become available, this review provides a comprehensive overview 
of evaluations previously performed and could be helpful in the realization of future 
economic evaluations.
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Objectives: Valganciclovir (VGV) is an antiviral agent used as prophylaxis of 
cytomegalovirus (CMV) infection following solid organ transplant. Limited studies 
regarding CMV prophylaxis with VGV in liver transplant recipients (LTR) have been 
performed. This study is a cost effectiveness analysis of VGV prevention strategies 
in LTR from a payer perspective. MethOds: We evaluated the cost of preventing 
hospitalization due to CMV in LTR at moderate to high risk of CMV. A decision 
tree model was constructed using TreeAge 2013. Data source for effectiveness was 
used from the results of our single-center retrospective analysis and cost data were 
from previously published data and the RedBook®. The model included costs of 
CMV prophylaxis, rates of CMV viremia, costs of outpatient treatment, and rates 
of inpatient admission due to CMV. We compared two protocols, one using lower 
doses and shorter duration of VGV prophylaxis (Group A) to a more recent protocol 
utilizing both higher doses and longer duration of VGV prophylaxis (Group B). Costs 
expressed in 2013 US dollars. Results: Costs associated with prophylaxis in group 
A were lower, despite a higher percentage of patients requiring treatment. Cost 
per-patient for prophylaxis in group A was $8,535.42 versus $14,926.73 in group 
B. In patients with CMV infection, 50% required hospitalization regardless of VGV 
prophylaxis group. Thus, 10% of patients in group A were hospitalized for treatment 
of CMV infection and only 4% of patients in group B required hospitalization. An 
ICER demonstrated that the prevention of one inpatient hospitalization due to CMV 
would cost $106,521.83. A one-way sensitivity analysis varying cost of VGV based 
on previously published costs demonstrated that the ICER for group B varies from 
$70,316 to $131,902. cOnclusiOns: While the increased dose and duration of VGV 
is effective at preventing CMV infection and hospitalization, it is associated with 
a large incremental cost.
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Objectives: Cigarette smoking increases the risk of postoperative complications. 
Preoperative smoking cessation programs may reduce surgical and post-operative 
complications, as well as the costs associated with treating them. We aimed to 
create an economic evaluation framework to estimate the potential value of pre-
operative smoking cessation programs for patients undergoing elective colorec-
tal surgery. MethOds: A decision-analytic model was developed from the payer 
perspective to integrate the costs and incidence of post-operative complications 
for a patient undergoing elective colorectal surgery after a smoking cessation 
program versus usual care. Incidence of post-operative complications in the 
first 30 days for smokers and recent quitters were derived from a cohort of 1,543 
patients undergoing elective colorectal resections in Washington State’s Surgical 
Care and Outcomes Assessment Program (2011-2013). Costs, smoking cessation 
program efficacy and alternative probabilities were obtained from the literature. 
Sensitivity analyses were performed to account for uncertainty in these esti-
mates. Results: For a cohort of 5,000 patients undergoing a preoperative smoking 
cessation program, the base case estimates imply the prevention of 9 respiratory 
complications, 16 infectious complications, and 2 thromboembolic complications, 
but there would be 4 more cardiovascular complications. The total direct medical 
costs of complications for patients who underwent a preoperative smoking ces-
sation program were on average $138 lower per patient than those in the usual 
care group during the first 30 days after surgery. The model was most sensitive 
to smoking cessation program effectiveness, but remained dominant across all 
sensitivity analyses. cOnclusiOns: A preoperative smoking cessation program 
is predicted to be cost-saving in the short term given the base case smoking ces-
sation efficacy of 22% if the cost of the intervention per patient is below $140. This 
framework allows payers to determine the value of smoking cessation programs 
of variable cost and effectiveness.
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initiating IFX treatment between 7/1/2007 and 7/31/2011. Index date was the date of 
first IFX claim; 6 months pre- and 12 months post-index were required. Medication 
Possession Ratio (MPR) was calculated as [total days on IFX therapy based on infu-
sion dates and assumed duration of action/360 days]; at least two infusions were 
required. MPR thresholds of ≥ 80% and ≥ 60% were used to classify adherent patients. 
All-cause and CD-related costs per patient per month by place of service were calcu-
lated, adjusted to 2011 dollars. Results: A total of 173 patients were identified, 156 
of which had at least 2 infusions. Mean age was 47.9 years, 59.5% were female, and 
53.8% had Commercial coverage. Across the MPR thresholds, adherent patients had 
significantly higher all-cause physician office visit costs, and lower other outpatient 
visit, emergency department and hospitalization costs than non-adherent patients. 
CD-related costs showed similar trends for physician office visit, other outpatient 
visit and hospitalization costs. IBD-drug related costs were significantly higher in 
the adherent group; all-cause pharmacy costs were similar between those adherent 
and non-adherent. Total CD-related costs were higher among adherent patients (80% 
MPR, $2532.5(±1439.8) vs. $1949.3(±1395.1), p-value 0.0002), while total all-cause costs 
were similar between groups (80% MPR, $3236.(±1717.0) vs. $3084.8(±1859.4), p-value 
0.2564). cOnclusiOns: Although adherent patients have higher physician office 
visit and IBD-drug related costs, hospitalization cost was significantly higher for 
non-adherent patients resulting in similar total all-cause costs for both the adher-
ent and non-adherent groups. Further research should quantify the clinical value 
of greater adherence against this backdrop of cost neutrality.
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Objectives: There is little research regarding the cost effectiveness of ostomy 
pouching systems. There is also limited evidence regarding the patient preferences 
of these devices. The aim was to investigate the patient preferences of individual 
characteristics of ostomy pouching systems. The aim was also to rank these char-
acteristics based on patient preferences. MethOds: All ostomy pouching systems, 
within the Swedish reimbursement system, were documented and their individual 
characteristics (i.e. properties of the filter, base plate and pouch material etc) iden-
tified both for closed-end and open-end bags. The significance of the identified 
characteristics was validated by a group of stoma nurses and experts. A pilot test 
of the interview guide for the focus group interviews were also held, resulting in 
small changes of the guide. Stoma nurses at nine different clinics in in different 
areas of Sweden consecutively asked stoma patients to participate. Patients were 
included if they gave oral and written consent, had a colostomy or ileostomy for at 
least one year. The patients were requested, together with the other participants 
in the focus group, to rank these individual characteristics of the ostomy pouching 
systems. Results: In total, 53 patients were included in the nine focus groups 
performed (one from each of the nine participating clinics). The top ranked patient 
preferences regarding closed-end bags were that the filter should reduce smell and 
should not leak but also that the base plate has good adhesive properties as well 
as being skin friendly. The top ranked patient preferences regarding open-end bags 
were also that the filter should reduce smell and should not leak. The bag should 
be easy to empty but also that the base plate has good adhesive properties as well 
as being skin friendly. cOnclusiOns: The top-ranked patient preferences were 
mainly characteristics regarding the filter and base plate.
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Objectives: Canadian inflammatory bowel disease (IBD) patients treated with 
infliximab are predominantly managed through a nationwide case management 
system, named BioAdvance, providing access to care, educational tools, supplies and 
assistance programs. The aim of this study was to identify underlying factors that 
were associated with positive changes in health outcomes. MethOds: Between 
August 1 and September 30, 2012, a web-based survey was provided to patients cur-
rently receiving infliximab therapy within BioAdvance. The cross-sectional survey 
included items on demographic, disease characteristics, services usage and prefer-
ence, and perception of health and work absenteeism. Patients were categorized 
according to health trajectories: declined in health (decliners), no improvement 
(non-changers), moderate improvement and large improvements (strong increas-
ers). Multivariable multinomial logistic regression was used to determine which 
factors were associated with different health trajectories. Results: 918 of 1160 
respondents were IBD patients reporting health status. Patients were treated for 
Crohn’s disease [CD] (66.1%), Ulcerative Colitis [UC] (26.6%) or 2 or more conditions 
(7.3%). Strong increasers were most prevalent (53.2%) and decliners least preva-
lent (3.7%). Strong increasers were more likely to use educational tools than non-
changers (adjusted odds ratio [aOR]: 1.65; 95% confidence interval [CI]: 1.03-2.64), to 
be treated for UC than CD (aOR: 2.05; 95%CI: 1.16-3.64) and to perceive BioAdvance 
as important (aOR: 2.52; 95%CI: 1.56-4.09). There were no factors distinguishing 
decliners from non-changers. Younger patients were less likely to miss workdays, as 
were French speaking patients and, consistent health trajectories, patients treated 
for UC (aOR: 0.68; 95%CI: 0.47-0.97). Patients were more likely to have missed work-
days prior to joining BioAdvance (aOR: 2.76; 95%CI: 2.02-3.76). cOnclusiOns: IBD 
patients receiving infliximab within the nationwide case management system 
report a positive impact on health status and absenteeism. Our study identified 
factors about the program that aremore impactful (educational tools) and patient 
factors that could improve program outcomes.
impairment, and numerically greater decreases in absenteeism, versus placebo at 
all study weeks. Differences relative to placebo in change from baseline to Week 
26 were -0.3% for absenteeism (NS), -5.9% for presenteeism, -7.5% for overall work 
productivity loss, and -6.7% for daily activity impairment (all 3 P< 0.05). Assuming a 
40-hour work week, linaclotide reduced overall work productivity loss by 3.0 hours/
week at Week 26. This translates to 156 hours/year which, based on average US 
wages, corresponds to an avoided overall work loss of $93 per patient/week or $4,861 
per patient/year. cOnclusiOns: Compared with placebo, once-daily linaclotide 
treatment significantly reduced overall work productivity loss and activity impair-
ment among IBS-C patients, with improvements seen at all measured time points 
over 26 weeks of treatment.
GastroIntestInal dIsorders – Patient-reported outcomes & Patient  
Preference studies
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Objectives: To examine the association between adherence and site of care 
among individuals with inflammatory bowel disease (IBD) treated with inflixi-
mab. MethOds: Adult patients with new claim(s) for infliximab (no claims for at 
least 360 days) between January 1, 2006 to December 31, 2009 and ≥ 2 IBD diagno-
ses of Crohn’s disease (CD; ICD-9-CM: 555.XX) or ulcerative colitis (UC; ICD-9-CM: 
556.XX) were identified from Thomas Reuters Marketscan® Databases. Patients were 
required to be continuously enrolled for 12 months before and after infliximab 
initiation (index date). Patients with evidence of another biologic or rheumatoid 
arthritis (ICD-9-CM: 714.XX) were excluded. Being adherent was defined as having 
an infliximab medication possession ratio (MPR) of ≥ 80%. MPR was calculated as 
the sum of unduplicated days of therapy based on infusion dates and duration of 
action from prescribing information, divided by 360 days. Site of care was obtained 
from the first infliximab infusion claim. Sites were divided into three settings: office, 
outpatient hospital and “other” (e.g., home, ER). Odds of being adherent versus 
non-adherent were compared for these settings in a logistic model controlling for 
patient characteristics and resource use variables. Results: 1646 IBD patients were 
identified; 57.4% CD and 42.6% UC. The mean (SD) age was 44.4 (15.6) years and 51.7% 
were male. On index, 1,052 (63.9%) patients had a site of care for office on their first 
infliximab infusion claim, 510 (31.0%) had outpatient hospital, and 84 (5.1%) had 
“other”. Patients in the office setting had greater odds of being adherent relative 
to outpatient hospital (p< 0.0001; OR 2.5, 95% CI [1.9, 3.2]) and ‘other’ (p= 0.0039; 
OR 2.1, 95% CI [1.3, 3.4]). Outpatient hospital was not significantly different than 
the ‘other’ location (p= 0.5204). cOnclusiOns: Findings suggest that having an 
office site of care is associated with increased infliximab adherence relative to the 
outpatient hospital setting.
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Objectives: To describe adherence in Crohn’s disease (CD) patients receiving 
infliximab (IFX) by site-of-care (SOC). MethOds: The Humana claims database 
was utilized to identify patients aged 18-89 with CD newly initiating IFX treatment 
between 7/1/2007 and 7/31/2011. Index date was the date of first IFX claim; 6 months 
pre- and 12 month post-index were required. Medication Possession Ratio (MPR) 
was calculated as [sum days’ supply of IFX based on infusion dates and assumed 
duration of action]/[sum days’ between first infusion and last days supply of last 
infusion]; therefore patients required ≥ 2 infusions. SOC types included physician 
office, outpatient hospital department, and ambulatory infusion centers. SOC was 
classified as ≥ 75% of infusions from one site; patients without a majority of infu-
sions from one site were classified as mixed-site. Results: A total of 173 patients 
were identified; 156 had at least 2 infusions. Mean age was 47.9 years, 59.5% were 
female, and 53.8% had Commercial coverage. Hospital outpatient (48.0%) and physi-
cian office (36.4%) were the most common SOC for index dose; among those who 
reached the maintenance phase, this same trend was observed. Mean MPR was 
similar across SOC (range 0.8 to 0.9, p-value 0.4412). Further, the proportion of 
patients considered adherent (≥ 80% MPR) was 72.4% among patients with physi-
cian office as primary SOC. The proportion of patients with ≥ 80% MPR in the other 
site types were similar to that of physician office patients (61.3%, 71.4%, and 81.0% 
for hospital outpatient, ambulatory infusion centers, and mixed site, respectively; 
p-value= NS). cOnclusiOns: IFX adherence rates among CD patients did not vary 
significantly across different sites of care. Research evaluating other factors, such 
as patients’ preferences and satisfaction, may be useful in further characterizing 
available sites of care and supporting optimal site of care selection.
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Objectives: To describe health care costs among Crohn’s disease (CD) patients 
receiving infliximab (IFX) by different adherence thresholds. MethOds: The 
Humana claims database was utilized to identify patients aged 18-89 with CD newly 
